NASDAQ:NGM NGM Biopharmaceuticals (NGM) Stock Price, News & Analysis → They said crypto was dead. It went up 100X. (From InvestorPlace) (Ad) Free NGM Stock Alerts $1.56 -0.01 (-0.64%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.55▼$1.5750-Day Range$1.26▼$1.9252-Week Range$0.60▼$4.69Volume1.05 million shsAverage Volume1.49 million shsMarket Capitalization$130.20 millionP/E RatioN/ADividend YieldN/APrice Target$3.68 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get NGM Biopharmaceuticals alerts: Email Address NGM Biopharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside136.1% Upside$3.68 Price TargetShort InterestHealthy3.13% of Float Sold ShortDividend StrengthN/ASustainability-0.54Upright™ Environmental ScoreNews Sentiment-0.26Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.13) to ($0.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.28 out of 5 starsMedical Sector162nd out of 947 stocksPharmaceutical Preparations Industry70th out of 435 stocks 3.0 Analyst's Opinion Consensus RatingNGM Biopharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.68, NGM Biopharmaceuticals has a forecasted upside of 136.1% from its current price of $1.56.Amount of Analyst CoverageNGM Biopharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.13% of the float of NGM Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverNGM Biopharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NGM Biopharmaceuticals has recently decreased by 1.81%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNGM Biopharmaceuticals does not currently pay a dividend.Dividend GrowthNGM Biopharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNGM Biopharmaceuticals has received a 75.70% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for NGM Biopharmaceuticals is -0.54. Previous Next 1.0 News and Social Media Coverage News SentimentNGM Biopharmaceuticals has a news sentiment score of -0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for NGM Biopharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for NGM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added NGM Biopharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NGM Biopharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders35.90% of the stock of NGM Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.06% of the stock of NGM Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NGM Biopharmaceuticals are expected to grow in the coming year, from ($1.13) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NGM Biopharmaceuticals is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NGM Biopharmaceuticals is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNGM Biopharmaceuticals has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCentral Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About NGM Biopharmaceuticals Stock (NASDAQ:NGM)NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 which is in phase I clinical trial for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.Read More NGM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NGM Stock News HeadlinesMarch 13, 2024 | businesswire.comNGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGMMarch 13, 2024 | americanbankingnews.comNGM Biopharmaceuticals (NASDAQ:NGM) Downgraded by Raymond James to "Market Perform"March 18, 2024 | Porter & Company (Ad)My next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.March 12, 2024 | bizjournals.comHow a VC and a biotech founder plan to create a new biotech modelMarch 12, 2024 | msn.comOracle, Dollar General upgraded: Wall Street's top analyst callsMarch 11, 2024 | globenewswire.comNGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 29, 2024 | msn.comTD Cowen Downgrades NGM Biopharmaceuticals (NGM)February 27, 2024 | businesswire.comNGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGMMarch 18, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… February 26, 2024 | bizjournals.comThe Column Group moves forward with plan to take NGM Bio privateFebruary 26, 2024 | finanznachrichten.deNGM Biopharmaceuticals, Inc.: NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LPFebruary 26, 2024 | markets.businessinsider.comNGM Bio To Be Acquired By Affiliates Of The Column Group, LPFebruary 26, 2024 | finance.yahoo.comNGM to go private through deal with investment firmFebruary 26, 2024 | marketwatch.comNGM Biopharmaceuticals Shares Drop 20% After $1.55/Shr Buyout OfferFebruary 26, 2024 | businesswire.comNGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to ShareholdersFebruary 26, 2024 | marketwatch.comNGM Biopharmaceuticals Gets Buyout Offer From Column Group AffliatesFebruary 26, 2024 | msn.comNGM Bio to go private in a $135M deal with Atlas NeonFebruary 26, 2024 | globenewswire.comNGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LPFebruary 22, 2024 | finance.yahoo.comAscites Market to Observe Stunning Growth During the Study Period (2019–2032) | DelveInsightFebruary 20, 2024 | finance.yahoo.comNGM Bio to Participate in the Cowen 44th Annual Health Care ConferenceFebruary 20, 2024 | globenewswire.comNGM Bio to Participate in the Cowen 44th Annual Health Care ConferenceFebruary 13, 2024 | ca.finance.yahoo.comNGM Biopharmaceuticals, Inc. (NGM)January 19, 2024 | benzinga.comLooking Into NGM Biopharmaceuticals's Recent Short InterestJanuary 17, 2024 | finance.yahoo.comNGM Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceJanuary 9, 2024 | msn.comNGM Biopharma gains on Phase 1 data update for cancer therapyJanuary 9, 2024 | benzinga.comNGM Biopharmaceuticals Stock (NASDAQ:NGM) Dividends: History, Yield and DatesJanuary 9, 2024 | finance.yahoo.comNGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet NeedSee More Headlines Receive NGM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NGM Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/18/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NGM CUSIPN/A CIK1426332 Webwww.ngmbio.com Phone(650) 243-5555FaxN/AEmployees239Year Founded1998Price Target and Rating Average Stock Price Target$3.68 High Stock Price Target$6.00 Low Stock Price Target$1.55 Potential Upside/Downside+136.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-162,670,000.00 Net Margins-3,223.34% Pretax Margin-3,223.34% Return on Equity-77.85% Return on Assets-67.76% Debt Debt-to-Equity RatioN/A Current Ratio7.79 Quick Ratio7.92 Sales & Book Value Annual Sales$4.42 million Price / Sales29.46 Cash FlowN/A Price / Cash FlowN/A Book Value$3.18 per share Price / Book0.49Miscellaneous Outstanding Shares83,460,000Free Float53,499,000Market Cap$130.20 million OptionableOptionable Beta1.26 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. William J. Rieflin J.D. (Age 64)Executive Chairman of the Board of Directors Comp: $1.1MDr. David J. Woodhouse Ph.D. (Age 53)CEO & Director Comp: $860.75kMs. Valerie L. Pierce J.D. (Age 61)Senior VP, General Counsel, Secretary & Chief Compliance Officer Comp: $580.75kDr. Hsiao Dee Lieu F.A.C.C. (Age 54)M.D., Chief Medical Officer & Executive VP Comp: $625.75kJean Frederic Viret Ph.D.Chief Financial OfficerMs. Irene PerlichVP, Corporate Controller & Principal Accounting OfficerMr. Daniel Kaplan Ph.D.Chief Scientific OfficerAnthony Kuhlmann Ph.D.Head of Intellectual PropertyDiana Peng BockusHead of Business DevelopmentArthur Hsu Ph.D.Senior Director & Head of BiologyMore ExecutivesKey CompetitorsAdageneNASDAQ:ADAGImmunicNASDAQ:IMUXGalectin TherapeuticsNASDAQ:GALTEmergent BioSolutionsNYSE:EBSSyros PharmaceuticalsNASDAQ:SYRSView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 9,472 shares on 3/11/2024Ownership: 3.349%Goldman Sachs Group Inc.Sold 162,679 shares on 3/1/2024Ownership: 0.134%GSA Capital Partners LLPBought 120,797 shares on 2/16/2024Ownership: 0.404%Vanguard Group Inc.Bought 9,472 shares on 2/15/2024Ownership: 3.350%Barclays PLCBought 52,331 shares on 2/15/2024Ownership: 0.110%View All Institutional Transactions NGM Stock Analysis - Frequently Asked Questions Should I buy or sell NGM Biopharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NGM Biopharmaceuticals in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NGM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NGM, but not buy additional shares or sell existing shares. View NGM analyst ratings or view top-rated stocks. What is NGM Biopharmaceuticals' stock price target for 2024? 4 brokerages have issued 12 month target prices for NGM Biopharmaceuticals' stock. Their NGM share price targets range from $1.55 to $6.00. On average, they predict the company's share price to reach $3.68 in the next year. This suggests a possible upside of 136.1% from the stock's current price. View analysts price targets for NGM or view top-rated stocks among Wall Street analysts. How have NGM shares performed in 2024? NGM Biopharmaceuticals' stock was trading at $0.8590 on January 1st, 2024. Since then, NGM stock has increased by 81.6% and is now trading at $1.56. View the best growth stocks for 2024 here. When is NGM Biopharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our NGM earnings forecast. How were NGM Biopharmaceuticals' earnings last quarter? NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.03. The business had revenue of $18.58 million for the quarter, compared to analysts' expectations of $18.90 million. NGM Biopharmaceuticals had a negative trailing twelve-month return on equity of 77.85% and a negative net margin of 3,223.34%. What is David Woodhouse's approval rating as NGM Biopharmaceuticals' CEO? 3 employees have rated NGM Biopharmaceuticals Chief Executive Officer David Woodhouse on Glassdoor.com. David Woodhouse has an approval rating of 34% among the company's employees. This puts David Woodhouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. When did NGM Biopharmaceuticals IPO? (NGM) raised $100 million in an IPO on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen served as the underwriters for the IPO. Who are NGM Biopharmaceuticals' major shareholders? NGM Biopharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.35%), Vanguard Group Inc. (3.35%), Federated Hermes Inc. (0.42%), GSA Capital Partners LLP (0.40%), BNP Paribas Financial Markets (0.27%) and Bridgeway Capital Management LLC (0.24%). Insiders that own company stock include David J Woodhouse, David V Goeddel, Group L P Column, Hsiao D Lieu and Jin-Long Chen. View institutional ownership trends. How do I buy shares of NGM Biopharmaceuticals? Shares of NGM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NGM) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NGM Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.